BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 29752320)

  • 41. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.
    Vignot S; Frampton GM; Soria JC; Yelensky R; Commo F; Brambilla C; Palmer G; Moro-Sibilot D; Ross JS; Cronin MT; André F; Stephens PJ; Lazar V; Miller VA; Brambilla E
    J Clin Oncol; 2013 Jun; 31(17):2167-72. PubMed ID: 23630207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On Predicting lung cancer subtypes using 'omic' data from tumor and tumor-adjacent histologically-normal tissue.
    Pineda AL; Ogoe HA; Balasubramanian JB; Rangel Escareño C; Visweswaran S; Herman JG; Gopalakrishnan V
    BMC Cancer; 2016 Mar; 16():184. PubMed ID: 26944944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
    Planchard D; Remon J; Nowak F; Soria JC
    Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
    [No Abstract]   [Full Text] [Related]  

  • 44. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.
    Chau NG; Hurwitz S; Mitchell CM; Aserlind A; Grunfeld N; Kaplan L; Hsi P; Bauer DE; Lathan CS; Rodriguez-Galindo C; Tishler RB; Haddad RI; Sallan SE; Bradner JE; French CA
    Cancer; 2016 Dec; 122(23):3632-3640. PubMed ID: 27509377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.
    Oshita F; Kasajima R; Miyagi Y
    J Exp Ther Oncol; 2016 Jul; 11(3):189-194. PubMed ID: 28471124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].
    Belilovski Rozenblum A; Ilouze M; Dudnik E; Soussan-Gutman L; Dvir A; Peled N
    Harefuah; 2017 Nov; 156(11):686-691. PubMed ID: 29198084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
    Devarakonda S; Morgensztern D; Govindan R
    Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "Personalizing" therapy for non-small cell lung cancer.
    D'Cunha J
    Semin Thorac Cardiovasc Surg; 2010; 22(2):118-20. PubMed ID: 21092888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
    Kasaian K; Wiseman SM; Walker BA; Schein JE; Zhao Y; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
    BMC Cancer; 2015 Dec; 15():984. PubMed ID: 26680454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
    Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
    Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genomics of lung cancer may change diagnosis, prognosis and therapy.
    Kopper L; Tímár J
    Pathol Oncol Res; 2005; 11(1):5-10. PubMed ID: 15800676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
    Santarpia L; Bottai G; Kelly CM; Győrffy B; Székely B; Pusztai L
    Oncologist; 2016 Sep; 21(9):1063-78. PubMed ID: 27384237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
    McCullar B; Pandey M; Yaghmour G; Hare F; Patel K; Stein K; Feldman R; Chandler JC; Martin MG
    Breast Cancer Res Treat; 2016 Jul; 158(1):195-202. PubMed ID: 27329168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene expression profiling and non-small-cell lung cancer: where are we now?
    Santos ES; Blaya M; Raez LE
    Clin Lung Cancer; 2009 May; 10(3):168-73. PubMed ID: 19443336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile.
    Goto T; Hirotsu Y; Mochizuki H; Nakagomi T; Shikata D; Yokoyama Y; Oyama T; Amemiya K; Okimoto K; Omata M
    Oncotarget; 2017 May; 8(19):31133-31143. PubMed ID: 28415711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC.
    Zhao X; Wang A; Walter V; Patel NM; Eberhard DA; Hayward MC; Salazar AH; Jo H; Soloway MG; Wilkerson MD; Parker JS; Yin X; Zhang G; Siegel MB; Rosson GB; Earp HS; Sharpless NE; Gulley ML; Weck KE; Hayes DN; Moschos SJ
    PLoS One; 2015; 10(6):e0129280. PubMed ID: 26076459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.
    Ross K; Pailler E; Faugeroux V; Taylor M; Oulhen M; Auger N; Planchard D; Soria JC; Lindsay CR; Besse B; Vielh P; Farace F
    Expert Rev Mol Diagn; 2015; 15(12):1605-29. PubMed ID: 26564313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.